About Protagonist Therapeutics
Protagonist Therapeutics is a company based in Milpitas (United States) founded in 2001. Protagonist Therapeutics has raised $67 million across 10 funding rounds from investors including HHS, RA Capital and Canaan. The company has 126 employees as of December 31, 2024. Protagonist Therapeutics offers products and services including Icotrokinra and Hepcidin Mimetic. Protagonist Therapeutics operates in a competitive market with competitors including Aclaris Therapeutics, OMass Therapeutics, Prometheus Biosciences, Enterome and Kanvas Biosciences, among others.
- Headquarter Milpitas, United States
- Employees 126 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Protagonist Therapeutics, Inc.
-
Annual Revenue
$434.43 M (USD)624.05as on Dec 31, 2024
-
Net Profit
$275.19 M (USD)0as on Dec 31, 2024
-
EBITDA
$255.81 M (USD)0as on Dec 31, 2024
-
Total Equity Funding
$67 M (USD)
in 10 rounds
-
Latest Funding Round
Not available
-
Investors
HHS
& 11 more
-
Employee Count
126
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Protagonist Therapeutics
Protagonist Therapeutics is a publicly listed company on the NASDAQ with ticker symbol PTGX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Protagonist Therapeutics
Protagonist Therapeutics offers a comprehensive portfolio of products and services, including Icotrokinra and Hepcidin Mimetic.
Investigational therapy targeting IL-23 receptor for inflammatory diseases
Potential treatment for blood disorders through peptide innovation
People of Protagonist Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Protagonist Therapeutics
Protagonist Therapeutics has successfully raised a total of $67M across 10 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Protagonist Therapeutics
Protagonist Therapeutics has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, RA Capital and Canaan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Canaan is recognized as an early-stage venture capital firm.
|
Locked | Locked | Locked | |
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Locked | Locked | Locked | |
|
Early-stage life sciences investments are targeted in the healthcare sector.
|
Locked | Locked | Locked |
Investor details for Protagonist Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Protagonist Therapeutics
Investment portfolio details for Protagonist Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Protagonist Therapeutics
Detailed financials for Protagonist Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Protagonist Therapeutics Comparisons
Peer comparison for Protagonist Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Protagonist Therapeutics
Protagonist Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, OMass Therapeutics, Prometheus Biosciences, Enterome and Kanvas Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Proprietary mass spectrometry technologies are developed for protein assembly analysis.
|
|
| Locked | Locked | Locked |
Drugs for gastrointestinal diseases are developed using clinical biobanks.
|
|
| Locked | Locked | Locked |
Developer of immunomodulators for cancer and auto-immune diseases
|
|
| Locked | Locked | Locked |
Imaging solutions for microbial research and infectious diseases are provided.
|
Detailed competitors of Protagonist Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Protagonist Therapeutics
Complete news archive for Protagonist Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Protagonist Therapeutics
Protagonist Therapeutics was founded in 2001 and raised its 1st funding round 5 years after it was founded.
Protagonist Therapeutics is headquartered in Milpitas, United States. It is registered at Milpitas, California, United States.
Dinesh Patel is the current CEO of Protagonist Therapeutics.
Protagonist Therapeutics is a funded company, having raised a total of $67M across 10 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Protagonist Therapeutics is 126.
Annual revenue of Protagonist Therapeutics is $434.43M as on Dec 31, 2024.
Protagonist Therapeutics was founded in 2001 and is headquartered in Milpitas, United States. Focus is placed on the biotechnology sector, where oral peptide therapeutics are developed for gastrointestinal conditions such as inflammatory bowel diseases and irritable bowel syndrome. The pipeline includes PTG-100, an α4β7 integrin antagonist, and IL-23 receptor antagonists for IBD treatment. Additional efforts target IL-6 as an anti-inflammatory agent and hepcidin mimetics for iron overload disorders.
Protagonist Therapeutics's top competitors include Aclaris Therapeutics, Prometheus Biosciences and OMass Therapeutics.
Protagonist Therapeutics offers Icotrokinra and Hepcidin Mimetic.
Yes, Protagonist Therapeutics is publicly traded on NASDAQ under the ticker symbol PTGX.
Protagonist Therapeutics has 12 investors. Key investors include HHS, RA Capital, Canaan, National Heart, Lung, and Blood Institute, and Adage Capital Management.
The ticker symbol of Protagonist Therapeutics is PTGX on NASDAQ.